WO2014130613A3 - Carbohydrate phosphonate derivatives as modulators of glycosylation - Google Patents

Carbohydrate phosphonate derivatives as modulators of glycosylation Download PDF

Info

Publication number
WO2014130613A3
WO2014130613A3 PCT/US2014/017271 US2014017271W WO2014130613A3 WO 2014130613 A3 WO2014130613 A3 WO 2014130613A3 US 2014017271 W US2014017271 W US 2014017271W WO 2014130613 A3 WO2014130613 A3 WO 2014130613A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycosylation
modulators
carbohydrate
phosphonate derivatives
phosphonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/017271
Other languages
French (fr)
Other versions
WO2014130613A2 (en
Inventor
John Gordon Allen
Christopher H. Fotsch
Michael J. Frohn
John Douglas MCCARTER
Mirna MUJACIC
Alexander J. Pickrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50238475&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2014130613(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to US14/767,737 priority Critical patent/US9328134B2/en
Priority to EP14708738.1A priority patent/EP2958905B1/en
Publication of WO2014130613A2 publication Critical patent/WO2014130613A2/en
Publication of WO2014130613A3 publication Critical patent/WO2014130613A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Compounds of Formula (I) are useful as modulators of glycosylation. Compounds of Formula (I) have the following structure: (I) and the definitions of the other variables are provided herein.
PCT/US2014/017271 2013-02-22 2014-02-20 Carbohydrate phosphonate derivatives as modulators of glycosylation Ceased WO2014130613A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/767,737 US9328134B2 (en) 2013-02-22 2014-02-20 Carbohydrate phosphonate derivatives as modulators of glycosylation
EP14708738.1A EP2958905B1 (en) 2013-02-22 2014-02-20 Carbohydrate phosphonate derivatives as modulators of glycosylation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361768175P 2013-02-22 2013-02-22
US61/768,175 2013-02-22

Publications (2)

Publication Number Publication Date
WO2014130613A2 WO2014130613A2 (en) 2014-08-28
WO2014130613A3 true WO2014130613A3 (en) 2014-11-06

Family

ID=50238475

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/017271 Ceased WO2014130613A2 (en) 2013-02-22 2014-02-20 Carbohydrate phosphonate derivatives as modulators of glycosylation

Country Status (3)

Country Link
US (1) US9328134B2 (en)
EP (1) EP2958905B1 (en)
WO (1) WO2014130613A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12606585B2 (en) 2020-09-09 2026-04-21 Stichting Radboud Universiteit Fluorinated hexoses

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021005949A (en) * 2018-11-22 2021-07-06 Idorsia Pharmaceuticals Ltd STABLE VACCINE AGAINST <i>CLOSTRIDIUM DIFFICILE.
US20230022796A1 (en) * 2019-12-19 2023-01-26 Merck Patent Gmbh Methods and compositions for modulating the glycosylation profile of proteins
EP4076490A1 (en) 2019-12-20 2022-10-26 Bristol-Myers Squibb Company Use of fucosylation inhibitor for producing afucosylated antibody
CN112645915B (en) * 2021-01-13 2021-10-08 广州安岩仁医药科技有限公司 Synthetic method of SGLT2 inhibitor intermediate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006120576A2 (en) * 2005-05-06 2006-11-16 Novartis Vaccines And Diagnostics Srl Immunogens for meningitidis-a vaccines
WO2009135181A2 (en) * 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2010141855A1 (en) * 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210078A (en) 1991-04-30 1993-05-11 The Biomembrane Institute Trifluoromethyl analogs of fucose and uses thereof
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP3513794A3 (en) 2010-08-05 2019-10-16 Seattle Genetics, Inc. Fucose analogs for inhibition of protein fucosylation in vivo
EP2887947B1 (en) 2012-08-23 2019-06-05 Seattle Genetics, Inc. Fucose analogues for the treatment of sickle cell disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006120576A2 (en) * 2005-05-06 2006-11-16 Novartis Vaccines And Diagnostics Srl Immunogens for meningitidis-a vaccines
WO2009135181A2 (en) * 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2010141855A1 (en) * 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CORY D. RILLAHAN ET AL: "High-Throughput Screening for Inhibitors of Sialyl- and Fucosyltransferases", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 50, no. 52, 23 December 2011 (2011-12-23), pages 12534 - 12537, XP055117415, ISSN: 1433-7851, DOI: 10.1002/anie.201105065 *
YU-NONG LIN ET AL: "Chemoenzymatic Synthesis of GDP-L-Fucose Derivatives as Potent and Selective [alpha]-1,3-Fucosyltransferase Inhibitors", ADVANCED SYNTHESIS & CATALYSIS, vol. 354, no. 9, 18 June 2012 (2012-06-18), pages 1750 - 1758, XP055117413, ISSN: 1615-4150, DOI: 10.1002/adsc.201100940 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12606585B2 (en) 2020-09-09 2026-04-21 Stichting Radboud Universiteit Fluorinated hexoses

Also Published As

Publication number Publication date
EP2958905A2 (en) 2015-12-30
WO2014130613A2 (en) 2014-08-28
EP2958905B1 (en) 2017-03-29
US20150376221A1 (en) 2015-12-31
US9328134B2 (en) 2016-05-03

Similar Documents

Publication Publication Date Title
EP2983514A4 (en) Carbohydrate compositions
PH12014502398B1 (en) Pesticidal compositions and processes related thereto
EP3055414A4 (en) Compositions for modulating c9orf72 expression
IN2015DN00598A (en)
PH12013500360B1 (en) Pesticidal compositions
WO2014121040A8 (en) Flap modulators
EP3086791A4 (en) Phenazine derivatives as antimicrobial agents
EP2948503B8 (en) Novel inorganic, halogen-free flameproofing agent on the basis of chemically modified recarbonized red mud
UA116395C2 (en) TRIASOL DERIVATIVES [4,5-b] PYRIMIDINE
EP3052638A4 (en) Glucosyl stevia composition
MY174000A (en) Novel pyridine derivatives
PH12013501654A1 (en) Pesticidal compositions and processes related thereto
EP3221312A4 (en) Substituted bridged urea analogs as sirtuin modulators
PH12015502665A1 (en) Improvements in or relating to organic compounds
IL241318A0 (en) Bicyclo[2.2.1] acid as modulators of 120gpr
EP3058084A4 (en) Sialylated glycoproteins
MX2016002217A (en) COMPOUNDS WITH PESTICIATED ACTIVITY.
EP3083555A4 (en) Processes for the diazotization of 2,5-dichloroanilines
MX2016004393A (en) Carboxamide derivatives as pesticidal compounds.
EP4458153A3 (en) Pesticide composition and method
HK1220622A1 (en) Physiological ligands for gpr139
WO2014172363A3 (en) Combretastatin analogs
GB2523518A (en) Absorbent article with absorbent structure with cross-directionally oriented passageway
EP2980064A4 (en) Novel inclusion compound
EP3024326A4 (en) Novel process for the preparation of levothyroxine sodium

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14708738

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14767737

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2014708738

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014708738

Country of ref document: EP